MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 29, 2006; DOI: 10.1124/mol.105.021204


0026-895X/06/7001-60-70$20.00
Mol Pharmacol 70:60-70, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.021204v1
mol.105.021204v2
70/1/60    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mulligan, J. M.
Right arrow Articles by Zisterer, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulligan, J. M.
Right arrow Articles by Zisterer, D. M.

Identification of Tubulin as the Molecular Target of Proapoptotic Pyrrolo-1,5-benzoxazepines

Jude M. Mulligan, Lisa M. Greene, Suzanne Cloonan, Margaret M. Mc Gee, Valeria Onnis, Giuseppe Campiani, Caterina Fattorusso, Mark Lawler, D. Clive Williams, and Daniela M. Zisterer

School of Biochemistry and Immunology, Trinity College, Dublin, Ireland (J.M.M., L.M.G., S.C., V.O., D.C.W., D.M.Z.); Conway Institute of Molecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland (M.M.M.); Dipartimento Farmaco Chimico Tecnologico, Universita' degli Studi di Siena, Siena, Italy (G.C., C.F.); and the Institute of Molecular Medicine, St James's Hospital and Trinity College, Dublin, Ireland (M.L.)

We have demonstrated previously that certain members of a series of novel pyrrolo-1,5-benzoxazepine (PBOX) compounds potently induce apoptosis in a variety of human chemotherapy-resistant cancer cell lines and in primary ex vivo material derived from cancer patients. A better understanding of the molecular mechanisms underlying the apoptotic effects of these PBOX compounds is essential to their development as antineoplastic therapeutic agents. This study sought to test the hypothesis that proapoptotic PBOX compounds target the microtubules. We show that a representative proapoptotic PBOX compound, PBOX-6, induces apoptosis in both the MCF-7 and K562 cell lines. An accumulation of cells in G2/M precedes apoptosis in response to PBOX-6. PBOX-6 induces prometaphase arrest and causes an accumulation of cyclin B1 levels and activation of cyclin B1/CDK1 kinase in a manner similar to that of two representative antimicrotubule agents, nocodazole and paclitaxel. Indirect immunofluorescence demonstrates that both PBOX-6 and another pro-apoptotic PBOX compound, PBOX-15, cause microtubule depolymerization in MCF-7 cells. They also inhibit the assembly of purified tubulin in vitro, whereas a nonapoptotic PBOX compound (PBOX-21) has no effect on either the cellular microtubule network or on the assembly of purified tubulin. This suggests that the molecular target of the pro-apoptotic PBOX compounds is tubulin. PBOX-6 does not bind to either the vinblastine or the colchicine binding site on tubulin, suggesting that it binds to an as-yet-uncharacterised novel site on tubulin. The ability of PBOX-6 to bind tubulin and cause microtubule depolymerization confirms it as a novel candidate for antineoplastic therapy.


Received December 12, 2005; accepted March 29, 2006

Address correspondence to: Dr. Daniela Zisterer, School of Biochemistry and Immunology, Trinity College, Dublin 2, Ireland. E-mail: dzistrer{at}tcd.ie




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
L. M. Greene, G. Campiani, M. Lawler, D. C. Williams, and D. M. Zisterer
BubR1 Is Required for a Sustained Mitotic Spindle Checkpoint Arrest in Human Cancer Cells Treated with Tubulin-Targeting Pyrrolo-1,5-Benzoxazepines
Mol. Pharmacol., February 1, 2008; 73(2): 419 - 430.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. M. Greene, L. Kelly, V. Onnis, G. Campiani, M. Lawler, D. C. Williams, and D. M. Zisterer
STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia Cells
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 288 - 297.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics